STYLE SHEET
GLOBAL CSS
COLORS
ANIMATIONS
MEDIA QUERY
SPACING SYSTEM

Why only for healthcare professionals?

The content on these information pages is directed solely at you if you are a doctor, nurse, or pharmacist, as it concerns treatment with prescription medicines.

Please confirm that you are a healthcare professional (healthcare assistant, nurse, doctor, psychologist, or other licensed healthcare professional).

Back to main page

Confirm and continue

News
August 22, 2025

Express: Gemma Collins' weight loss transformation with Yazen jabs

Express: Gemma Collins' weight loss transformation with Yazen jabs

Gemma Collins unveils incredible transformation with Yazen’s weight loss jabs

Reality star Gemma Collins has stunned fans by revealing her dramatic weight loss, dropping two dress sizes after starting weight loss programme through Yazen. Sharing her journey on Instagram, Gemma expressed excitement about feeling “healthier, happier, and finally free” from the pressures of dieting.

The TOWIE star, who has struggled with weight loss for years, shared that Yazen's personalised medical support has been life-changing, allowing her to focus on long-term health and confidence.

Read the full article on Espress.

More news

WOD26: Data Reveals Persistent Shame & Stigma Around Obesity Treatment

Ahead of World Obesity Day on 4 March, Yazen is sharing new findings from internal patient data, revealing that shame and stigma remain major barriers to obesity care — even as effective medical treatments become more widely available.

UK firms eye GLP-1 benefits to cut sick leave and boost performance.

UK employers are increasingly considering weight-loss support as part of employee benefits, as new Yazen patient data links GLP-1 treatment to reduced sick days and improved workplace performance.

Yazen achieved record-breaking growth in 2025, doubling its revenue.

In 2025, Yazen's revenue surged 87% to nearly €29.4 million, with gross profits doubling to €16.5 million. Now treating over 37,000 active patients across seven countries, the company is eyeing further expansion into two more markets in 2026. Despite an EBITDA of –€5.7 million due to heavy growth investment, Yazen remains a leader in European obesity care.